Get the Stockscreener App
0.486
0.82%
-0.004
Spruce Biosciences Inc stock is traded at $0.486, with a volume of 71,690.
It is down -0.82% in the last 24 hours and down -11.10% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).
See More
Previous Close:
$0.49
Open:
$0.476
24h Volume:
71,690
Relative Volume:
0.19
Market Cap:
$19.66M
Revenue:
$9.57M
Net Income/Loss:
$-43.11M
P/E Ratio:
-0.291
EPS:
-1.67
Net Cash Flow:
$-49.54M
1W Performance:
-6.72%
1M Performance:
-11.10%
6M Performance:
-36.63%
1Y Performance:
-64.53%
1-Day Range:
$0.476
$0.5039
1-Week Range:
$0.4716
$0.52
52-Week Range:
$0.4112
$5.95
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| SPRB | 0.4898 | 19.66M | 9.57M | -43.11M | -49.54M | -1.67 |
| VRTX | 448.21 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.76 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.48 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.71 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
Layoff Tracker: Gilead Sciences Will Lay Off 104 Employees at California HQ - BioSpace
ARMISTICE CAPITAL, LLC Acquires New Stake in Spruce Biosciences Inc - GuruFocus.com
Spruce Biosciences Inc (SPRB) Quarterly 10-Q Report - Quartzy
Spruce Biosciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Scholz Advisers Slash German Growth Forecast for Next Year - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont's fate hangs on Q4 trial results - Investing.com Canada
EchoStar Q3 Earnings Lag Estimates on Lower Revenues, Stock Down 13% - Yahoo Finance
Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence? - TipRanks
Spruce Biosciences Reports Q3 2024 Earnings and Updates - Yahoo Finance
Should Value Investors Buy Silvercorp Metals (SVM) Stock? - Yahoo Finance
Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates - MSN
US opens probe into 1.4 million Honda vehicles over engine issues - Yahoo Canada Finance
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Why Cambium (CMBM) International Revenue Trends Deserve Your Attention - Yahoo Finance
Spruce Biosciences Trims Losses, Eyes Critical Clinical Data in December | SPRB Stock News - StockTitan
Don't Race Out To Buy Enbridge Inc. (TSE:ENB) Just Because It's Going Ex-Dividend - Yahoo Finance
Caribou Biosciences (NASDAQ:CRBU) vs. Sutro Biopharma (NASDAQ:STRO) Financial Analysis - Defense World
Brokerages Set Element Solutions Inc (NYSE:ESI) Target Price at $31.00 - Defense World
Vitro Diagnostics (OTCMKTS:VODG) and Tectonic Therapeutic (NASDAQ:TECX) Critical Comparison - Defense World
Analysts Set Spruce Biosciences, Inc. (NASDAQ:SPRB) Price Target at $5.00 - Defense World
Spruce Biosciences faces Nasdaq delisting notice - Investing.com India
Spruce Biosciences faces Nasdaq delisting notice By Investing.com - Investing.com South Africa
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference - Business Wire
Global Adrenogenital Syndrome Treatment Market to Reach USD 22.08 Billion in 2033, Driven by New The - PharmiWeb.com
Congenital Adrenal Hyperplasia Clinical Trials 2024: FDA Approvals, Companies, Medication, Treatment Market, Therapies, ROA and MOA by DelveInsight | Becton, Dickinson and Company, Cook Medical, MORE - Barchart
Floyd Mayweather Jr buying $402M Black Spruce portfolio - Yahoo Finance
Congenital Adrenal Hyperplasia (CAH) Therapeutic Market 2024 - openPR
Ambev S.A. (NYSE:ABEV) Given Average Rating of “Hold” by Brokerages - Defense World
Daily Progress: Spruce Biosciences Inc (SPRB) Drop -5.56, Closing at 0.43 - The Dwinnex
The Significance of Moving Averages in Spruce Biosciences Inc Inc. (SPRB) Price Performance - The InvestChronicle
A closer look at Spruce Biosciences Inc (SPRB)’s stock price trends - US Post News
North Carolina town that produces quartz needed for tech products is devastated by Helene - Yahoo Finance
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock - Investing.com
Spruce Biosciences' SWOT analysis: tildacerfont trials key for CAH stock By Investing.com - Investing.com UK
Neurocrine Biosciences's Crinecerfont is Set to Transform the Congenital Adrenal Hyperplasia Treatment Market | DelveInsight - PR Newswire
Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily
Spruce Biosciences Inc (SPRB) expanding its growth trajectory ahead - SETE News
Spruce Biosciences Inc [SPRB] stock for 350,951 USD was sold by Novo Holdings A/S - Knox Daily
Spruce Biosciences Inc’s results are impressive - US Post News
Financial Fitness Check: Examining Spruce Biosciences Inc (SPRB)’s Key Ratios - The Dwinnex
Checking in on Spruce Biosciences Inc (SPRB) after recent insiders movement - Knox Daily
Life Time Group Holdings Inc (LTH) gets rating Initiated from Craig Hallum - Knox Daily
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Potential Price Increase for Spruce Biosciences Inc (SPRB) After Recent Insider Activity - Knox Daily
SPRBSpruce Biosciences, Inc. Latest Stock News & Market Updates - StockTitan
An Inquiry Has Been Launched Into Whether Spruce Biosciences Inc. Violated Securities Regulations And Stockholders Are Encouraged To Assist - StockTitan
Spruce Biosciences Inc (SPRB) Becoming More Attractive for Investors - Knox Daily
SPRB (Spruce Biosciences) Profitability Rank : 1 (As of Jun. 2024) - GuruFocus.com
SPRB (Spruce Biosciences) Dividends per Share : $0.00 (TTM As of Jun. 2024) - GuruFocus.com
Spruce Power Holding Second Quarter 2024 Earnings: US$0.46 loss per share (vs US$0.17 profit in 2Q 2023) - Yahoo Finance
Spruce Biosciences (NASDAQ:SPRB) Issues Quarterly Earnings Results, Beats Expectations By $0.10 EPS - Defense World
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Spruce Biosciences Inc Stock (SPRB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Novo Holdings A/S | 10% Owner |
Mar 18 '24 |
Sale |
0.77 |
842,020 |
647,008 |
3,968,000 |
| Novo Holdings A/S | 10% Owner |
Mar 19 '24 |
Sale |
0.76 |
593,000 |
447,715 |
3,375,000 |
| Novo Holdings A/S | 10% Owner |
Mar 20 '24 |
Sale |
0.73 |
359,979 |
264,081 |
3,015,021 |
| Novo Holdings A/S | 10% Owner |
Mar 14 '24 |
Sale |
0.89 |
1,912,316 |
1,698,902 |
4,810,020 |
| Charlton Ralph William III | Chief Medical Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
31,750 |
0 |
56,992 |
| Gharib Samir M. | President & CFO |
Dec 15 '23 |
Option Exercise |
0.00 |
112,250 |
0 |
204,403 |
| Szwarcberg Javier B. | Chief Executive Officer |
Dec 15 '23 |
Option Exercise |
0.00 |
111,000 |
0 |
145,705 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):